Rapport Therapeutics (RAPP) and Its Competitors Critical Survey

Rapport Therapeutics (NASDAQ:RAPP) is one of 1,072 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Rapport Therapeutics to similar companies based on the strength of its analyst recommendations, risk, earnings, profitability, institutional ownership, valuation and dividends.

Valuation and Earnings

This table compares Rapport Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Rapport Therapeutics	N/A	-$34.79 million	-0.66
Rapport Therapeutics Competitors	$9.89 billion	$136.37 million	-5.81

Rapport Therapeutics’ rivals have higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Rapport Therapeutics and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	0	0	4	0	3.00
Rapport Therapeutics Competitors	8423	22280	50479	1352	2.54

Rapport Therapeutics presently has a consensus target price of $32.67, indicating a potential upside of 259.96%. As a group, “Pharmaceutical preparations” companies have a potential upside of 244.82%. Given Rapport Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Rapport Therapeutics is more favorable than its rivals.

Profitability

This table compares Rapport Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	N/A	N/A
Rapport Therapeutics Competitors	-3,399.87%	-235.11%	-32.77%

Institutional and Insider Ownership

44.0% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 13.7% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Rapport Therapeutics beats its rivals on 7 of the 12 factors compared.

About Rapport Therapeutics

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.